In this segment, the panel discusses how clinicians may incorporate emerging therapies into the management of Sjögren’s Disease (SjD) as new agents approach approval. They emphasize the importance of patient stratification, noting that treatment decisions should reflect disease phenotype, degree of systemic involvement, and biomarkers indicating B-cell activation or interferon-driven pathways. As therapies such as BAFF/APRIL inhibitors, CD40–CD40L blockers, FcRn inhibitors, and TYK2 inhibitors progress through trials, clinicians will need to determine which mechanisms match which patient profiles.

The panel also stresses the role of shared decision-making, particularly when introducing newly approved or first-in-class agents. They acknowledge that integrating new treatments will require education, comfort with new safety monitoring processes, and coordination across specialties. Ultimately, the group expresses optimism that these emerging therapies will allow more personalized, targeted, and effective treatment strategies, shifting SjD care from symptomatic management toward true disease modification.